Pharming Group (OTCMKTS:PHGUF) Shares Gap Down – What’s Next?

Pharming Group NV (OTCMKTS:PHGUF) shares gapped down before the market opened on Thursday . The stock had previously closed at $1.75, but opened at $1.2480. Pharming Group shares last traded at $1.18, with a volume of 3,848 shares traded.

Pharming Group Stock Performance

The company has a quick ratio of 2.03, a current ratio of 2.59 and a debt-to-equity ratio of 0.39. The stock has a market cap of $836.96 million, a P/E ratio of 62.39 and a beta of 0.55. The stock has a fifty day simple moving average of $1.60 and a 200-day simple moving average of $1.65.

Pharming Group (OTCMKTS:PHGUF) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a return on equity of 4.68% and a net margin of 3.30%.The company had revenue of $72.45 million for the quarter, compared to the consensus estimate of $92.06 million.

About Pharming Group

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.